Treatment Options

1. Use a β-Lactam (ceftazidime or cefepime) or β-lactam-β-lactamase inhibitor combination (piperacillin-tazobactam or cefoperazone-sulbactam) if in-vitro susceptibility is demonstrated
2. Aminoglycosides (if in-vitro susceptibility is demonstrated)
3. Polymyxins (for infections in which no other treatment option is available)

• For patients with severe infections caused by CRPA susceptible in vitro only to polymyxins, aminoglycosides, or fosfomycin, a combination therapy is suggested. Polymyxins plus other agent to which organism has demonstrated susceptible MIC or in intermediate range or SDD (susceptible dose dependent) can be used in such scenario. (Consultation with an Infectious Disease Physician or a physician having experience in treating such infections is advised)
• In patients with non-severe infections or among patients with low risk CRPA infections monotherapy to be considered on an individual basis according to the source of infection